All In MedTech

FDA Clearance Tracker · P950037-S280

Solia CSP S 53; Solia CSP S 60

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 12, 2026

Approved

Time to decision

114 days

Received Oct 21, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P950037-S280
Device name
Solia CSP S 53; Solia CSP S 60
Applicant location
Lake Oswego, OR
Received
Oct 21, 2025
Decided
Feb 12, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P950037

Device type

Device class
Class III

Every decision under product code NVN

FDA's approval statement

As written in FDA's record.

Approval for the Solia CSP S pacing leads intended for implantation in the left bundle branch area.

Source documents

Other decisions for Biotronik, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.